Big pharma giant Pfizer has been forced to pause its trial of a drug for a rare muscle-wasting disease after a child who received it died suddenly.
“A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study,” the company revealed in an online letter.
They said the participant, a young boy suffered acardiac arrest and died after receiving Pfizers one time treatment last year. He was part of a mid-stage study, now concluded, that enrolled children between the ages of 2 and 4 years old.
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
You can unsubscribe any time. By subscribing you agree to our Terms of Use
NDTV reports: Pfizer has paused administering the same gene therapy in a separate, final-stage study while it investigates the boy’s death, the company said. That study is looking at the gene therapy, called fordadistrogene movaparvovec, to treat Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease that primarily affects boys.
Pfizer said it’s working to “evaluate our investigational gene therapy while protecting the safety of the participants, which is our top priority.”
The final-stage trial enrolled boys between the ages of 4 and 8, testing whether the therapy could slow disease progression compared to a placebo. Results from that study are expected this year.
